The USFDA has granted fast-track designation to AiCuris’ Letermovir, an inhibitor of the human cytomegalovirus. iCuris CEO Helga Rübsamen-Schaeff said that the fast-track status will hopefully facilitate the regulatory process for the drug and support the company’s view that Letermovir has the potential to become the treatment of choice for patients at risk of human cytomegalovirus.